Dr. Mohammad Keykhaei was analyzing Medicare data when he and his UCLA Health colleagues uncovered something striking: heart failure patients who received all four recommended medications were hospitalized 87% fewer times for their condition in the year after discharge. For a disease that sends older Americans to the hospital repeatedly and costs the health system tens of thousands per patient annually, the finding offers a clear path forward—if clinicians can actually implement it.
Heart failure with reduced ejection fraction, or HFrEF, is one of the most common reasons older adults end up hospitalized in the United States. The condition means the heart cannot pump blood effectively enough to meet the body's needs, and many patients return to the hospital again and again. Each stay is expensive. The researchers found that the average one-year total health care cost after a heart failure hospitalization was $41,802 per patient, with $25,172 of that coming directly from hospitalizations themselves.
The UCLA Health team, led by Dr. Gregg Fonarow, director of the Ahmanson-UCLA cardiomyopathy center, examined real-world Medicare data from more than 50,000 patients age 65 or older. They looked at what happens when patients receive quadruple guideline-directed medical therapy—all four drug classes that national treatment guidelines recommend and that randomized clinical trials have proven reduce hospitalizations and improve outcomes. What they discovered matters: implementing this full four-drug approach could reduce hospitalizations related to heart failure by 87% and cut all-cause hospitalizations by 61%, translating to savings of nearly $10,000 per patient per year in hospitalization costs alone.
The paradox is that this therapy combination is underused. Despite decades of evidence that these four medications work together to save lives and reduce repeat hospital visits, many patients never receive all four—a persistent gap in heart failure care that costs the system and costs patients.
The economic analysis revealed complexity worth noting. Some expensive medication combinations resulted in higher net costs, especially when newer drugs were used. But here's the encouraging part: many lower-priced or generic versions of these drugs produced overall savings even after accounting for medication spending. When the researchers modeled various drug-pricing scenarios, most showed net savings when optimal therapy was used. As drug prices continue to evolve and more medications become available in generic form, the financial case for quadruple therapy will likely strengthen.
What makes this research valuable is its grounding in real-world data rather than controlled trials. Dr. Keykhaei and his colleagues didn't rely on models extracted from clinical trials; they used actual Medicare claims data to calculate the combined economic impact of implementing all four therapies in a contemporary population. This matters because it shows that the benefits observed in research translate to actual savings in everyday practice.
For clinicians and health systems, the implications are straightforward: closing the treatment gap between guidelines and practice could simultaneously improve patient outcomes and reduce costs. The challenge now is removing barriers to access, improving how medications are initiated and optimized at hospital discharge, and ensuring that more patients actually receive the full course of therapy recommended by national guidelines. In heart failure care, the science has already spoken. The work ahead is making that science standard practice.